Certain blood pressure lowering medications may have dangerous side effects as researchers have found a link between taking vasodilators and developing early-stage age-related macular degeneration (AMD) that could lead to vision loss and blindness.
AMD - the deterioration of the eye's macula, which is responsible for the ability to see fine details clearly - affects millions worldwide.
"As significant as these results may be, it is important that they be replicated first, and if possible tested in a clinical trials setting before changing anyone's medication regimens," cautioned Ronald Klein from University of Wisconsin's school of medicine and public health.
To reach this conclusion, the researchers conducted a long-term population-based cohort study from 1988 to 2013 of nearly 5,000 people aged 43 to 86 years.
After adjusting for age, sex and other factors, the researchers found that using any vasodilator such as Apresoline and Loniten, which open (dilate) the blood vessels - was associated with a 72 percent greater risk of developing early-stage AMD.
Among people who were not taking vasodilators, an estimated 8.2 percent developed signs of early AMD.
In comparison, among those taking a vasodilator medication, 19.1 percent developed the disease.
While the study provides risk estimates of associations between blood pressure lowering medications and AMD at various stages, the researchers cautioned that their study was not able to discern effects of the medications themselves and the conditions for which participants were taking those medications.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
